COMPARISON OF MULTIMORBIDITY IN COVID-19 INFECTED AND GENERAL POPULATION IN PORTUGAL

Miguel Froes INESC-ID
Instituto Superior Técnico
Universidade de Lisboa
Lisboa, Portugal
miguel.froes@tecnico.ulisboa.pt

Bernardo Neves
Departmento de Medicina Interna
Hospital da Luz
Lisboa, Portugal

Bruno Martins
INESC-ID
Instituto Superior Técnico
Universidade de Lisboa
Lisboa, Portugal

Mário J. Silva
INESC-ID
Instituto Superior Técnico
Universidade de Lisboa
Lisboa, Portugal

August 24, 2020

ABSTRACT

Understanding COVID-19 and its risk factors in the Portuguese population is critical to combat this condition. To study the impact of multimorbidity in the population with COVID-19 infection, we performed a descriptive analysis of a dataset extracted from all reported confirmed cases of COVID-19 in Portugal until June 30, 2020. We observed a prevalence of multimorbidity in 6.77% of the 36,244 infected patients. Patients showed an increased risk of hospitalization, ICU admission and mortality with OR 2.22 (CI 95%: 2.13-2.32) for every additional morbidity. Further studies should confirm these findings and special attention should be made on data collection to ensure proper recording of patient comorbidities.

Keywords Multimorbidity · COVID-19 · Chronic health conditions · Portugal · National Health Survey

1 Introduction

COVID-19 is an infectious disease caused by SARS-CoV-2 that started challenging health systems in recent months. Its impact is global with 21,200,000 cases and 761,000 deaths by August 16, 2020 [1]. Early evidence from this pandemic suggested that older patients with chronic conditions were over-represented and may herald a poor clinical course. However, data is still largely limited to China and Italy [2, 3]. Given that multimorbidity increases with age, the specific risk of different chronic conditions and their combination in terms of poor health outcomes needs to be adjusted for age, which is not routinely done [4]. Understanding which groups are at higher risk is important to better inform public health policies, resource allocation and advance knowledge about this novel condition.

DGS (Directionate-General of Health), the Portuguese public health authority, developed and operates SINAVE (National Epidemiological Surveillance System), the national public health surveillance system, to collect, update, analyze, and disclose data related to mandatory reporting infectious diseases and other public health hazards [5]. Symptoms, previous medical history, disease course and laboratory results are introduced by physicians in charge of COVID-19 patients. Although this platform was not specifically designed for this outbreak, it has been used since the beginning of the pandemic as the main official source of data about COVID-19 cases in Portugal.

---

[0]**Abbreviations:** SINAVE, Sistema Nacional de Vigilância Epidemiológica; COVID-19, Coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, multimorbidity, chronic conditions

In this work, we evaluate the prevalence of multimorbidity and age-adjusted risk of hospitalization, ICU admission and death in the Portuguese population from official data, based on a dataset extracted from SINAVE containing all confirmed cases of COVID-19 in Portugal by June 30, 2020. The last version of the above-mentioned dataset, April 28 2020, was previously analyze in the first version of this article. However, being the most recent version more complete and well reported, we chose to present only results from the June version and only mention the April version to discuss possible worsening or improvements in the dataset.

2 Methods

2.1 Sample

This retrospective observational study used data provided by DGS after the required institutional and ethical approvals. The sample population consists of all the Portuguese population with SARS-CoV2 confirmed infection as notified by clinicians by June 30, 2020. A broad range of clinical and demographic variables are present in this dataset. In this study we specifically used age, gender, hospital admission, admission in intensive care unit, mortality and patient's underlying conditions.

2.2 Measures

Chronic conditions were provided as a categorical variable on the presence, absence or unknown status of the following conditions: asthma, malignancy, cardiac disorder (including hypertension), chronic hematological disorder, diabetes, HIV/other immune deficiency, renal disease, liver disease, chronic lung disease, and neuromuscular disorder. A field containing the "raw" input from doctors was also taken into account and a text-mining script, for keywords associated with the above-mentioned conditions, was developed in order to truly represent the prevalence of the diseases. We defined multimorbidity as the presence of two or more conditions in the same individual, following the definition used by other authors [6]. Addressed outcomes were hospitalization, admission to ICU unit, and reported death. A composite outcome of any of these events was also analyzed.

2.3 Statistical analysis

We used *Python 3.6* and packages *Numpy*, *Pandas*, *Seaborn*, and *SciPy* in combination with *Microsoft Excel* to evaluate and plot the prevalence of multimorbidity. Additionally, *IBM SPSS Statistics* was used for obtaining age-adjusted risk of hospitalisation, ICU admission and death.

Categorical variables were presented as counts and percentages with 95% confidence intervals and comparisons were made using using the χ^2 test. Univariate regression analysis of each individual chronic condition was performed adjusting only for age. A multivariate logistic regression was performed adjusting for age and every other chronic condition with significant statistical association on univariate analysis. Results were considered significant when P <0,05.

3 Results

The overall sample contained 36,244 adult patient cases, women being more prevalent (56.66%). Among the cases, 18.79% had at least one chronic condition. Cardiac disorder was the most commonly reported condition, reported in 43.33% of the patients with any morbidity. Table 1 shows the reported prevalence of different chronic conditions in the studied population. Multimorbidity, as previously defined, was present in 6.77% of the cases. Figure 1 and Figure 2 plot the prevalence of multimorbidity by age group for the COVID-19 infected general population and hospitalized population, respectively. To analyze the Odd Ratio and prevalence of co-occurring pairs of chronic diseases, people with unknown disease prevalence were excluded, which resulted in a population of 33,283 adult patients. The prevalence of co-occurring pairs of chronic health conditions, plotted in Figure 4, shows Cardiac disorders and Diabetes as the most common dyad of chronic diseases.

Data regarding Hospitalization and ICU admission was available for only 32,945 patients (90.90% of the overall study population). Within this population, Hospitalization occurred in 12.89% of patients, with a male predominance (50.66%), and ICU admission was required for 4.11% of patients, with a female predominance (51.73%). Observed mortality was 3.19%. All chronic conditions except for asthma were associated with increased risk of mortality, and hospitalisation (Table 6 and 7, respectively). Age, diabetes, renal disease, lung disease, and neuromuscular disorders were all associated with increased risk of ICU admission (Table 8). Additionally, every additional chronic condition

Figure 1: Prevalence of multimorbidity by age group for the COVID-19 infected population. The lighter shade of blue is representative of the absence of conditions and the black line represents the prevalence of multimorbidity.

increases the risk of the composite outcome of death, hospitalisation or ICU admission by 123.3% (OR 2.22; CI 95%: 2.13-2.32).

4 Discussion

This study shows that multimorbidity is significantly associated with adverse outcomes in COVID-19 infection in the Portuguese population, independently from age. All chronic conditions, except asthma, lead to increased risk of hospitalization. However, only diabetes, chronic kidney disease, chronic respiratory diseases, and neuromuscular disorders are associated with more severe cases requiring ICU admission. These results are in line with previous reports where chronic diseases are associated with poorer outcomes [3, 7]. Although the strength of association differs between diseases, every additional morbidity leads to an increased risk of the composite outcome of hospitalization, ICU admission and mortality.

Multimorbidity was previously studied in the general Portuguese population in 2014 by Laires et al., using data from the fifth National Health Interview Survey (Inquérito Nacional de Saúde, INS) [6]. Prevalence of multimorbidity on the Laires at al. study can be compared with our data. Although only individuals aged 25-79 were included in that study, this constitutes a robust sample for morbidity prevalence in Portugal. We can observe in Figure 1 to Figure 3 a rise in chronic health conditions with increasing age as expected. However, multimorbidity is much less prevalent in our study population (6.39% vs 43.9%). Since the beginning of this pandemic there has been significant public awareness regarding the higher risk of older people with comorbidities. This may have induced efforts to protect and isolate this population. The findings of this study could thus confirm the positive effect of such measures, given the younger and healthier population in the COVID-19 dataset. The discrepancy may however be related to different reporting methods. For instance, the maximum number of significant reported simultaneous morbidities in the COVID-19 infected population was 5 disorders (there were a total of 5 people with simultaneous morbidities ranging from 6 to 8), which is half of the maximum number of morbidities found in the INS population (10 disorders). Since the total number of conditions between both datasets is not so different (COVID-19: 10 diseases; INS: 13 diseases), a possible explanation for the higher number of co-occurring conditions in the INS population can be the combination of self-diagnoses with the presence of more "subjective" disorders such as: lower and upper back pain, allergies, depression, and urinary incontinence.

Figure 2: Prevalence of multimorbidity by age group for the COVID-19 infected hospitalized population. The lighter shade of blue is representative of the absence of conditions and the black line represents the prevalence of multimorbidity.

Figure 3: Prevalence of multimorbidity by age group (Laires et al 2019) [6]. The lighter shade of blue is representative of the absence of conditions and the black line represents the prevalence of multimorbidity.

Figure 4: Prevalence of single (left) and co-occurring pairs (right) of chronic health conditions. Left: Prevalence of the disease in the population with at least one disease. Right: Prevalence of the disease, rows, in the population affected by another disease, columns. All values are presented in percentage.

Disease	Percentage (%)
CARDIAC DISORDER	43.86
DIABETES	30.94
NEUROMUSCULAR DISORDER	15.97
CANCER	14.22
ASTHMA	11.44
LUNG DISEASE	11.38
RENAL DISEASE	11.12
HEMATOLOGIC DISEASE	4.39
HIV	3.33
LIVER DISEASE	2.81

Figure 5 table (observed and expected co-occurring prevalence). First value = observed, second (italic) = expected:

	%	LBP	HTA	UBP	Arthrosis	Allergy	Depression	Diabetes	UI	COPD	Asthma	CKD	CHD	Stroke	MI	LC
LBP	34.8%	LBP														
HTA	26.5%	15.5 *9.2*	HTA													
UBP	25.6%	22.5 *8.9*	12.0 *6.8*	UBP												
Arthrosis	24.5%	18.5 *8.5*	13.3 *6.5*	15.5 *6.3*	Arthrosis											
Allergy	19.1%	9.8 *6.6*	6.2 *5.1*	7.9 *4.9*	6.5 *4.7*	Allergy										
Depression	13.0%	8.8 *4.5*	5.9 *3.4*	7.4 *3.3*	6.9 *3.2*	4.4 *2.5*	Depression									
Diabetes	9.8%	5.5 *3.4*	6.0 *2.6*	4.5 *2.5*	5.1 *2.4*	2.2 *1.9*	2.0 *1.3*	Diabetes								
UI	6.7%	4.8 *2.3*	4.0 *1.8*	3.9 *1.7*	4.3 *1.6*	1.8 *1.3*	2.4 *0.9*	1.9 *0.7*	UI							
COPD	5.6%	3.5 *1.9*	2.6 *1.5*	2.9 *1.4*	3.0 *1.4*	2.9 *1.1*	1.6 *0.7*	1.1 *0.5*	1.2 *0.4*	COPD						
Asthma	4.9%	2.7 *1.7*	1.8 *1.3*	2.2 *1.3*	2.0 *1.2*	3.0 *0.9*	1.2 *0.6*	0.8 *0.5*	0.8 *0.3*	2.5 *0.3*	Asthma					
CKD	4.5%	3.2 *1.6*	2.5 *1.2*	2.5 *1.2*	2.9 *1.1*	1.3 *0.9*	1.5 *0.6*	1.2 *0.4*	1.4 *0.3*	0.7 *0.3*	0.5 *0.2*	CKD				
CHD	3.6%	2.4 *1.3*	2.5 *1.0*	2.0 *0.9*	2.3 *0.9*	1.0 *0.7*	1.0 *0.5*	0.9 *0.4*	0.9 *0.2*	0.8 *0.2*	0.5 *0.2*	0.7 *0.2*	CHD			
Stroke	1.7%	0.9 *0.6*	1.3 *0.5*	0.8 *0.4*	1.0 *0.4*	0.3 *0.3*	0.5 *0.2*	0.4 *0.2*	0.4 *0.1*	0.2 *0.1*	0.1 *0.1*	0.3 *0.1*	0.3 *0.1*	Stroke		
MI	1.5%	1.0 *0.5*	1.2 *0.4*	0.8 *0.4*	0.9 *0.4*	0.3 *0.3*	0.4 *0.2*	0.6 *0.1*	0.4 *0.1*	0.3 *0.1*	0.3 *0.1*	0.3 *0.1*	0.6 *0.1*	0.2 *0.0*	MI	
LC	0.7%	0.5 *0.2*	0.4 *0.2*	0.4 *0.2*	0.4 *0.2*	0.2 *0.1*	0.2 *0.1*	0.2 *0.1*	0.2 *0.0*	0.1 *0.0*	0.1 *0.0*	0.2 *0.0*	0.1 *0.0*	0.1 *0.0*	0.1 *0.0*	LC

Legend: >10% | 5-10% | 1-5% | 0-1%

Figure 5: Relationship between the observed and expected prevalence of co-occurring pairs of chronic health conditions. All results are given in percentages. The shaded bar depicts the prevalence of each chronic health condition. In the matrix, the first value for each pair is the observed frequency, while the second (italic) is the expected one after multiplying the respective prevalence of each disorder. Chi-square tests were used to determine whether observed frequencies were significantly different from expected frequencies. All p-values were inferior to 5%.) LBP low back pain, HTA hypertension, UBP upper back pain, UI urinary incontinence, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, CHD coronary heart disease, MI previous myocardial infarction, and LC liver cirrhosis

(a)   (b)

Figure 6: Screenshots of SINAVE's interface regarding the report of known comorbidities: (a) Reporting the presence of comorbidities; (b) Reporting the known comorbidities

This study has several limitations. First of all, the cross-sectional nature of the COVID-19 dataset makes it impossible to account for incomplete outcomes, since several patients could ultimately be hospitalized or die after the end of observation. Reported data on outcomes may therefore be underestimated, so careful interpretation is advised until more data is available. More importantly, despite the fact that no standard set of conditions is established to define multimorbidity, chronic conditions were given on broad groups and there is no specific information on individual conditions. For example, diabetes is given as one group and no distinction is made between type 1 and type 2 diabetes. Therefore, measured morbidities may herald heterogeneous groups of diseases with different degrees of severity, which may influence outcomes. Future datasets should include more accurate information on chronic conditions.

Another important concern is related to the risk of under-reporting in this dataset, which becomes obvious by analyzing reported cardiac diseases. Given that cardiovascular diseases, particularly hypertension, are very prevalent in the Portuguese population [8], the observed prevalence of 8.14% in our study highly suggests that under-reporting may have occurred. However, it is important to stress that the prevalence of reported cardiac diseases as significantly increase since the first version of the provided dataset, dated from April 28, 2020 (cardiac disease prevalence in the general population of 0.28%). We could notice that, surprisingly, cardiovascular diseases are absent from the available list of previous conditions in SINAVE's reporting page, as seen in Figure 6b, which could have contributed to a lower notification of this comorbidity. One possible explanation to the considerable increase in cardiac disorder prevalence is the fact that "raw" input from doctors was included in the most recent version of the SINAVE's dataset (June 30, 2020).

Although we acknowledge that this dataset was not primarily designed for research, but rather for public health proceedings and government information, we believe that a better user interface design and a more rational set of chronic conditions could effortlessly improve the quality of recorded data. One important lesson we can learn from this pandemic is the important contribution that quickly gathered relevant clinical data and health information systems, such as SINAVE, can have in this setting.

Overall, we consider SINAVE to be very susceptible to under-reporting, specially regarding multimorbidity. This is due to a confusing and non-practical interface that allows doctors to skip filling some important fields in the entry form. Some suggestions to improve future studies regarding multimorbidity, using SINAVE's data, are:

- Redesign the reporting form, making data entry more effective and faster. The current user interface could be simplified, while encouraging the input of relevant comorbidity information;

- Integrate SINAVE data with the patient's health record or with data from the new *Trace Covid-19* system, to provide richer data relevant to COVID-19. This could be a way of implementing the redesigned user interface suggested above;

- Make it mandatory to input if comorbidities are absent; if present, the filling of the entry form inputs related to comorbidities and the specific chronic conditions should be mandatory. As seen in Figure 6, the list of comorbidities only becomes visible if a previous parameter is filled;

- Make the entry of all known chronic conditions by healthcare professionals more persuasive;

- Add cardiovascular diseases to the list of comorbidities.

To conclude, findings in our study show that multimorbidity is significantly associated with poor outcomes in COVID-19 infection. Further data is needed to inform about the strength of this association and about the significance of observed differences in multimorbidity prevalence between infected patients and the general population of Portugal. We believe that data collection problems may have occurred and influenced outcome measurement. We also provide recommendations for improving the data collection user interface that could improve quality of health information about the COVID-19 infected population, while increasing confidence in SINAVE data.

References

[1] WHO. World health organization. novel coronavirus (2019-ncov) situation reports.

[2] Nanshan Chen, Min Zhou, Xuan Dong, Jieming Qu, Fengyun Gong, Yang Han, Yang Qiu, Jingli Wang, Ying Liu, Yuan Wei, Jia'an Xia, Ting Yu, Xinxin Zhang, and Li Zhang. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet (London, England)*, 395(10223):507–513, 2020.

[3] Giacomo Grasselli, Alberto Zangrillo, Alberto Zanella, Massimo Antonelli, Luca Cabrini, Antonio Castelli, Danilo Cereda, Antonio Coluccello, Giuseppe Foti, Roberto Fumagalli, Giorgio Iotti, Nicola Latronico, Luca Lorini, Stefano Merler, Giuseppe Natalini, Alessandra Piatti, Marco Vito Ranieri, Anna Mara Scandroglio, Enrico Storti, Maurizio Cecconi, Antonio Pesenti, and COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA*, 323(16):1574, 2020.

[4] Kate E Mason, Philip McHale, Andy Pennington, Gillian Maudsley, Jennifer Day, and Ben Barr. Age-adjusted associations between comorbidity and outcomes of COVID-19: a review of the evidence. *medRxiv*, page 2020.05.06.20093351, 2020.

[5] DGS. https://www.dgs.pt/servicos-on-line1/sinave-sistema-nacional-de-vigilancia-epidemiologica.aspx.

[6] P. A. Laires and J. Perelman. The current and projected burden of multimorbidity: a cross-sectional study in a Southern Europe population. *European Journal of Ageing*, 16(2):181–192, 2019.

[7] Christopher M Petrilli, Simon A Jones, Jie Yang, Harish Rajagopalan, Luke O'Donnell, Yelena Chernyak, Katie A Tobin, Robert J Cerfolio, Fritz Francois, and Leora I Horwitz. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ*, 369:m1966, 2020.

[8] Jorge Polonia, Luis Martins, Fernando Pinto, and Jose Nazare. Prevalence, awareness, treatment and control of hypertension and salt intake in Portugal: changes over a decade. The PHYSA study. *Journal of Hypertension*, 32(6):1211–1221, 2014.

List of Tables

Table 1: Percentage of total population affected by comorbidity.

	Asthma	Cancer	Cardiac Disorder	Diabetes	Hematological Disorder	HIV	Renal Disease	Liver Disease	Lung Disease	Neuromuscular Disorder
Population (%)	2.10	2.68	8.14	5.92	0.89	0.60	2.09	0.57	2.18	3.09

Table 2: Odds Ratio for the outcome (Death) for the Age variable and analyzed comorbidities. The real value of Age was used instead of an age group. Being a continuous variable, an Odds Ratio of 1.097 implies that, as the Age variable increases by 1, the probability of the patient having the outcome increases by 9.7%. **B**, **S.E**, and **Wald** are the unstandardized regression weight, how much the unstandardized regression weight can vary by, and test statistic for the individual predictor variable, respectively.

	B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I	
							Lower	Upper
Age	,092	,002	1446,655	1	<0,001	1,097	1,092	1,102
Asthma	,188	,262	,515	1	,473	1,207	,722	2,017
Cancer	1,021	,113	82,084	1	<0,001	2,775	2,225	3,461
Cardiac Disorder	,520	,081	41,384	1	<0,001	1,682	1,435	1,970
Diabetes	,723	,087	69,373	1	<0,001	2,061	1,739	2,444
Hematologic Disease	,997	,175	32,438	1	<0,001	2,711	1,924	3,822
HIV	1,330	,306	18,837	1	<0,001	3,780	2,074	6,892
Renal Disease	1,177	,108	118,925	1	<0,001	3,244	2,626	4,008
Liver Disease	1,437	,253	32,137	1	<0,001	4,207	2,560	6,914
Lung Disease	,897	,117	58,276	1	<0,001	2,452	1,948	3,087
Neuromuscular Disease	1,092	,091	143,005	1	<0,001	2,981	2,492	3,565

Table 3: Odds Ratio for the outcome (Hospitalization) for the Age variable and analyzed comorbidities. The real value of Age was used instead of an age group. Being a continuous variable, an Odds Ratio of 1.056 implies that, as the Age variable increases by 1, the probability of the patient having the outcome increases by 5.6%. **B**, **S.E**, and **Wald** are the unstandardized regression weight, how much the unstandardized regression weight can vary by, and test statistic for the individual predictor variable, respectively.

	B	**S.E.**	**Wald**	**df**	**Sig.**	**Exp(B)**	**95% C.I**	
							Lower	**Upper**
Age	,054	,001	3180,583	1	<0,001	1,056	1,054	1,058
Asthma	,085	,130	,429	1	,513	1,088	,844	1,403
Cancer	1,251	,076	271,427	1	<0,001	3,493	3,010	4,054
Cardiac Disorder	,815	,049	277,596	1	<0,001	2,258	2,052	2,486
Diabetes	1,205	,054	494,291	1	<0,001	3,335	2,999	3,709
Hematologic Disease	1,772	,144	151,367	1	<0,001	5,882	4,435	7,801
HIV	1,538	,158	94,268	1	<0,001	4,654	3,412	6,348
Renal Disease	2<0,001	,091	478,288	1	<0,001	7,387	6,175	8,836
Liver Disease	1,885	,166	128,229	1	<0,001	6,584	4,751	9,123
Lung Disease	1,307	,086	232,600	1	<0,001	3,694	3,123	4,369
Neuromuscular Disease	1,536	,076	409,383	1	<0,001	4,645	4,003	5,390

Table 4: Odds Ratio for the outcome (ICU stay) for the Age variable and analyzed comorbidities. The real value of Age was used instead of an age group. Being a continuous variable, an Odds Ratio of 1.052 implies that, as the Age variable increases by 1, the probability of the patient having the outcome increases by 5.2. **B**, **S.E**, and **Wald** are the unstandardized regression weight, how much the unstandardized regression weight can vary by, and test statistic for the individual predictor variable, respectively.

	B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I	
							Lower	Upper
Age	,050	,002	1100,303	1	<0,001	1,052	1,048	1,055
Asthma	-,332	,251	1,744	1	,187	,718	,439	1,174
Cancer	,011	,136	,007	1	,935	1,011	,775	1,319
Cardiac Disorder	,026	,083	,101	1	,751	1,027	,873	1,208
Diabetes	,268	,088	9,255	1	,002	1,307	1,100	1,554
Hematologic Disease	,113	,215	,276	1	,600	1,119	,735	1,705
HIV	-,252	,419	,362	1	,547	,777	,342	1,767
Renal Disease	,369	,125	8,800	1	,003	1,447	1,134	1,847
Liver Disease	,392	,287	1,867	1	,172	1,479	,844	2,594
Lung Disease	,366	,128	8,152	1	,004	1,442	1,122	1,855
Neuromuscular Disease	,295	,107	7,605	1	,006	1,343	1,089	1,655

Table 5: Odds Ratio for the outcome (Death + Hospitalisation + ICU stay) for the Age variable and analyzed comorbidities. The real value of Age was used instead of an age group. Being a continuous variable, an Odds Ratio of 1.061 implies that, as the Age variable increases by 1, the probability of the patient having the outcome increases by 6.1%. **B**, **S.E**, and **Wald** are the unstandardized regression weight, how much the unstandardized regression weight can vary by, and test statistic for the individual predictor variable, respectively.

	B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I	
							Lower	Upper
Age	,059	,001	3654,861	1	<0,001	1,061	1,059	1,063
Asthma	,032	,130	,060	1	,806	1,033	,800	1,333
Cancer	1,216	,076	253,311	1	<0,001	3,373	2,904	3,918
Cardiac Disorder	,768	,049	248,499	1	<0,001	2,156	1,959	2,372
Diabetes	1,170	,054	464,558	1	<0,001	3,221	2,896	3,583
Hematologic Disease	1,747	,147	140,286	1	<0,001	5,736	4,296	7,658
HIV	1,537	,159	93,498	1	<0,001	4,649	3,405	6,348
Renal Disease	2,032	,094	463,142	1	<0,001	7,627	6,338	9,177
Liver Disease	1,811	,168	116,114	1	<0,001	6,115	4,399	8,501
Lung Disease	1,320	,087	231,704	1	<0,001	3,743	3,158	4,437
Neuromuscular Disease	1,586	,078	414,126	1	<0,001	4,886	4,194	5,693

Table 6: Odds Ratio for the association between the age, categories of comorbidity and outcome (Death) in patients with Covid-19. The continuous value of Age was used instead of an age group. Being a continuous variable, an Odds Ratio of 1.093 implies that, as the Age variable increases by 1, the probability of the patient having the outcome increases by 9.3%. **B**, **S.E**, and **Wald** are the unstandardized regression weight, how much the unstandardized regression weight can vary by, and test statistic for the individual predictor variable, respectively.

	B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I	
							Lower	Upper
Age	,089	,003	1157,213	1	<0,001	1,093	1,088	1,099
Cancer	,711	,119	35,639	1	<0,001	2,037	1,613	2,573
Cardiac Disorder	,257	,086	8,903	1	,003	1,293	1,092	1,530
Diabetes	,253	,096	6,887	1	,009	1,288	1,066	1,556
Hematologic Disease	,253	,186	1,864	1	,172	1,288	,896	1,854
HIV	,890	,320	7,750	1	,005	2,436	1,301	4,558
Renal Disease	,698	,118	35,218	1	<0,001	2,009	1,596	2,530
Liver Disease	,851	,270	9,917	1	,002	2,342	1,379	3,977
Lung Disease	,471	,125	14,146	1	<0,001	1,602	1,253	2,048
Neuromuscular Disease	,886	,095	87,857	1	<0,001	2,425	2,015	2,919

Table 7: Odds Ratio for the association between the age, categories of comorbidity and outcome (Hospitalisation) in patients with Covid-19. The continuous value of Age was used instead of an age group. Being a continuous variable, an Odds Ratio of 1.045 implies that, as the Age variable increases by 1, the probability of the patient having the outcome increases by 4.5%. **B**, **S.E**, and **Wald** are the unstandardized regression weight, how much the unstandardized regression weight can vary by, and test statistic for the individual predictor variable, respectively.

							95% C.I	
	B	**S.E.**	**Wald**	**df**	**Sig.**	**Exp(B)**	**Lower**	**Upper**
Age	,044	,001	1721,450	1	<0,001	1,045	1,043	1,047
Cancer	,916	,083	120,287	1	<0,001	2,498	2,121	2,942
Cardiac Disorder	,526	,054	93,696	1	<0,001	1,692	1,521	1,881
Diabetes	,719	,061	137,713	1	<0,001	2,053	1,821	2,315
Hematologic Disease	1,002	,162	38,278	1	<0,001	2,724	1,983	3,741
HIV	1,079	,176	37,594	1	<0,001	2,941	2,083	4,152
Renal Disease	1,396	,099	198,500	1	<0,001	4,041	3,327	4,907
Liver Disease	1,309	,184	50,593	1	<0,001	3,704	2,582	5,314
Lung Disease	,794	,095	69,540	1	<0,001	2,213	1,836	2,667
Neuromuscular Disease	1,323	,080	275,328	1	<0,001	3,756	3,212	4,391

Table 8: Odds Ratio for the association between the age, categories of comorbidity and outcome (ICU stay) in patients with Covid-19. The continuous value of Age was used instead of an age group. Being a continuous variable, an Odds Ratio of 1.050 implies that, as the Age variable increases by 1, the probability of the patient having the outcome increases by 5.0%. **B**, **S.E**, and **Wald** are the unstandardized regression weight, how much the unstandardized regression weight can vary by, and test statistic for the individual predictor variable, respectively.

	B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I	
							Lower	Upper
Age	,048	,002	943,562	1	<0,001	1,050	1,046	1,053
Diabetes	,177	,093	3,652	1	,056	1,194	,995	1,431
Renal Disease	,238	,130	3,335	1	,068	1,269	,983	1,638
Lung Disease	,270	,132	4,187	1	,041	1,309	1,011	1,695
Neuromuscular Disease	,231	,108	4,553	1	,033	1,260	1,019	1,558

Table 9: Odds Ratio for the association between the age, categories of comorbidity and outcome (Death + Hospitalisation + ICU stay) in patients with Covid-19. The continuous value of Age was used instead of an age group. Being a continuous variable, an Odds Ratio of 1.050 implies that, as the Age variable increases by 1, the probability of the patient having the outcome increases by 5.0%. **B**, **S.E**, and **Wald** are the unstandardized regression weight, how much the unstandardized regression weight can vary by, and test statistic for the individual predictor variable, respectively.

	B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I	
							Lower	Upper
Age	,049	,001	2160,553	1	<0,001	1,050	1,048	1,052
Cancer	,885	,084	111,355	1	<0,001	2,423	2,055	2,855
Cardiac Disorder	,480	,054	78,761	1	<0,001	1,616	1,454	1,797
Diabetes	,694	,061	127,705	1	<0,001	2,002	1,775	2,258
Hematologic Disease	,983	,166	35,153	1	<0,001	2,671	1,930	3,697
HIV	1,083	,176	37,806	1	<0,001	2,955	2,092	4,174
Renal Disease	1,446	,102	201,261	1	<0,001	4,246	3,477	5,184
Liver Disease	1,227	,186	43,534	1	<0,001	3,409	2,368	4,908
Lung Disease	,830	,096	74,757	1	<0,001	2,293	1,900	2,767
Neuromuscular Disease	1,375	,081	285,182	1	<0,001	3,957	3,373	4,642

Table 10: Odds Ratio for the association between the age, number of comorbidities and outcome (Death + Hospitalization + ICU stay) in patients with Covid-19. Both Age and N^o of comorbidities are continuous variables, i.e, an Odds Ratio of 2.223 implies that, as the N^o of comorbidities increases by 1, the probability of the patient having the outcome increases by 122.3%. **B**, **S.E**, and **Wald** are the unstandardized regression weight, how much the unstandardized regression weight can vary by, and test statistic for the individual predictor variable, respectively.

							95% C.I	
	B	**S.E.**	**Wald**	**df**	**Sig.**	**Exp(B)**	**Lower**	**Upper**
Age	,050	,001	2321,879	1	<0,001	1,051	1,049	1,053
N^{o}of comorbidities	,799	,023	1257,322	1	<0,001	2,223	2,127	2,323

Disease	Percentage (%)
CARDIAC DISORDER	43.86
DIABETES	30.94
NEUROMUSCULAR DISORDER	18.87
CANCER	14.22
ASTHMA	11.44
LUNG DISEASE	11.28
RENAL DISEASE	11.12
HEMATOLOGIC DISEASE	4.39
HIV	3.33
LIVER DISEASE	1.81

LBP 34.8%	LBP										>10%			
HTA 26.5%	13.5	HTA									5-10%			
UBP 25.6%	22.0	8.0	UBP								1-5%			
Arthrosis 24.5%	13.3	11.9	11.9	Arthrosis							0-1%			
Alergy 19.1%	11.9	6.3	11.0	7.3	Alergy									
Depression 18.0%	9.8	6.1	8.0	6.1	4.3	Depression								
Diabetes 9.8%	5.2	6.0	3.9	4.2	4.4	2.2	Diabetes							
UI 7.5%	5.9	3.0	2.8	1.9	1.0		1.9	UI						
COPD 4.9%	3.7								COPD					
Asthma 4.5%	2.7					1.2	2.6	1.4		Asthma				
CKD 4.5%	3.2										CKD			
CHD 3.6%	2.6											CHD		
Stroke 1.9%	2.5												Stroke	
MI 1.6%	0.2	0.9												MI
LC 0.7%															LC